Comparison · NCT01806259-ce5cec96
Ketorolac 30 mg vs NaCl 0.9% 3mL: Overall Survival
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ketorolac 30 mg vs NaCl 0.9% 3mL: Overall Survival. Trial comparisons, record NCT01806259-ce5cec96. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01806259-ce5cec96
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.969 | 0.912 | 0.989 | wilson | |
| Risk in group 2 | 0.981 | 0.934 | 0.995 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0126 | -0.0708 | 0.0387 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.987 | 0.944 | 1.03 | log | |
| Odds ratio, group 1 over group 2 | 0.59 | 0.0966 | 3.61 | log | |
| Number needed to treat, for one fewer participant with the outcome on Ketorolac 30 mg than on NaCl 0.9% 3mL | 79.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ketorolac 30 mg | Active drug to be compared with placebo~Ketorolac 30 mg IV | 93 | 96 | OG000 |
| Group 2 | NaCl 0.9% 3mL | Placebo looking like the Active drug | 105 | 107 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- OTHER_PRE_SPECIFIED
- Title
- Overall Survival
- Description
- 2 years for the primary analysis + 3 additional years for secondary analysis (From date of randomization until the date of death from any cause assessed up to 5 years)
- Time frame
- 5 years
- Population
Source ClinicalTrials.gov
Trial
- Title
- Ketorolac in Breast Cancer Surgery
- NCT number
- NCT01806259
- Phases
- PHASE3
- Conditions
- Curative Breast Cancer Surgery, Inflammatory Positive/Negative Status, Pre Surgical Incision Administration
- Interventions
- Ketorolac 30 mg IV, Placebos
- Lead sponsor
- Université Catholique de Louvain
- Results first posted
- 2020-01-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01806259?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01806259-ce5cec96